Market Overview

UPDATE: Bank of America Initiates Intercept Pharmaceuticals at Buy on Regulatory Outlook

Related ICPT
Markets Little Changed Ahead Of 4th Of July Break
Benzinga's Top Initiations

Bank of America initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy rating and a $29 price objective.

Bank of America noted, "We are initiating coverage of Intercept pharmaceuticals (ICPT) with a Buy rating and DCF derived $29 PO. ICPT is a development stage pharmaceutical company focused on bile acid derived therapeutics. The company's lead product is OCA, a bile acid derivative, for the treatment of a rare autoimmune liver disease, primary billiary cirrhosis (PBC). We expect OCA will report positive Phase 3 trial results (2014). Our PO incorporates a heavier than normal risk adjustment for US approval pending additional clarity on the regulatory pathway in 2013; success in additional indications (e.g. portal hypertension) represent upside to our PO."

Intercept Pharmaceuticals closed at $20.00 on Friday.

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (ICPT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free